Malignant Hyperthermia : Proceedings of the 3rd International Symposium on Malignant Hyperthermia, 1994

In susceptible individuals, malignant hyperthermia (MH) can be triggered by various anesthetics during surgery. First described in 1960, research since then has concentrated on reducing the very high mortality rate associated with MH. Although significant progress in treatment has been made with the introduction of dantrolene sodium in 1979, many questions remain unanswered. Following on the results of more than 30 years of investigative efforts, the Third International Symposium on MH was held in Hiroshima, Japan, in 1994, immediately before the Seventh International Workshop on MH. Specialists in the field discussed the most up-to-date findings from the point of view of clinical classification, history, and incidence based on the evidence of epidemiology, diagnostic muscle testing, genetics, and biochemistry. These proceedings of the symposium present important keys to understanding the mechanism of MH and related syndromes at the genetic level and include procedures for the monitoring and care of patients. This volume will be invaluable not only for surgeons and anesthesiologists but also for physiologists and researchers. Front Matter....Pages II-XV Front Matter....Pages 1-1 History of Malignant Hyperthermia....Pages 3-17 Front Matter....Pages 19-19 The Incidence of Malignant Hyperthermia in Denmark....Pages 21-24 Malignant Hyperthermia in Austria 1984–1993....Pages 25-32 Clinical Classification and Incidence of Fulminant and Abortive Malignant Hyperthermia Reactions in Italy....Pages 33-37 The Epidemiology of Malignant Hyperthermia Events in North America....Pages 39-41 Clinical Classification and Incidence of Malignant Hyperthermia in Australia....Pages 43-47 Clinical Classification and Incidence of Malignant Hyperthermia in Japan....Pages 49-56 Front Matter....Pages 57-57 Testing for Malignant Hyperthermia in North America and Australia....Pages 59-62 Muscular Testing of Malignant Hyperthermia in Europe....Pages 63-66 Caffeine Contracture of the Skinned Muscle Fiber in Malignant Hyperthermia and Neuromuscular Diseases....Pages 67-73 Calcium-Induced Calcium Release Test....Pages 75-75 Front Matter....Pages 77-77 Mutations in the Skeletal Muscle Ryanodine Receptor ( RYR1 ) Gene are Linked to Malignant Hyperthermia and Central-Core Disease....Pages 79-86 Chromosome 17 Candidate Gene Analysis in a Population Referred Because of Suspected Susceptibility to Malignant Hyperthermia....Pages 87-93 Disease Expression and Gene Expression Can Be Quite Distinct: Modulation of Skeletal Muscle Sodium Channels by the Human Myotonin Dystrophy Protein Kinase (HMPK)....Pages 95-101 Front Matter....Pages 103-103 Intracellular Calcium Release Channels in Muscles Related to Excitation-Contraction-Coupling and Malignant Hyperthermia....Pages 105-106 Metabolism of Inositol Polyphosphates by Malignant Hyperthermia-Susceptible and Control Porcine Skeletal Muscle....Pages 107-117 Fatty Acids: Potentially Crucial Modulators of the Malignant Hyperthermia Syndrome....Pages 119-128 Mitochondrial Disorders in Malignant Hyperthermia....Pages 129-136 Muscle Mitochondria and Malignant Hyperthermia....Pages 137-144 Front Matter....Pages 145-145 Association Between Malignant Hyperthermia and Severe, Chronic Muscle Pain....Pages 147-158 Front Matter....Pages 145-145 Porcine Malignant Hyperthermia....Pages 159-161 Vitamin E and Porcine Malignant Hyperthermia....Pages 163-171 Malignant Hyperthermia in Dogs....Pages 173-182 Heatstroke....Pages 183-186 Intracellular Calcium Mechanism in the Pathogenesis of Neuroleptic Malignant Syndrome....Pages 187-195 Controversies in the Pathogenesis of Neuroleptic Malignant Syndrome....Pages 197-202 Neuromuscular Disorders and Malignant Hyperthermia....Pages 203-210 Front Matter....Pages 211-211 Updated Therapy of Malignant Hyperthermia....Pages 213-217 Front Matter....Pages 219-219 “What Is Malignant Hyperthermia?”....Pages 221-244 Back Matter....Pages 245-256